Press

Filament Health Announces Termination of Shareholder Meeting and Engagement of Donohoe Advisory for Compliance Expertise

Dec 19 • 4 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of its securityholders held this Monday, December 18, 2023 at 9:30 a.m. (Vancouver time) (the “Special Meeting“) to approve, among other things, the Company’s proposed arrangement (the “Arrangement“) under Part 9, Division 5 of the Business Corporations…

Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer

Dec 18 • 3 min read

Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer Phase 2 trial demonstrated the safety and efficacy of psilocybin-assisted group therapy for treatment of major depressive disorder in patients with cancer Group setting and 1:1 patient-to-therapist ratio has potential to increase accessibility of psilocybin-assisted therapy Further publication gives insight into patient experience Sunstone…

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

Dec 18 • 2 min read

Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, “Novel Aza-Substituted Psilocin Analogs And…

Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study

Dec 15 • 3 min read

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for Beckley Psytech’s cutting-edge Phase 2b clinical trial…

Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses

Dec 14 • 3 min read

Beckley Academy, a leading training organization that prepares and trains practitioners with a focus on preparing mental health professionals to use ketamine, psilocybin, and MDMA to treat patients, announced today that Sara Gael Beauregard and Mary Sanders have joined the team as facilitators. Both Sara and Mary are psychedelic therapists with clinical experience working with training organizations to meet…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441